Kamal Mostafa 4
4 · MAGELLAN HEALTH INC · Filed Nov 17, 2020
Insider Transaction Report
Form 4
Kamal Mostafa
CEO, Magellan Rx Management
Transactions
- Exercise of In-Money
Ordinary Common Stock, $0.01 par value
2020-11-13$68.50/sh+13,282$909,817→ 18,899 total - Exercise of In-Money
Stock Option (right to buy)
2020-11-16−7,603→ 27,205 totalExercise: $66.57Exp: 2029-03-05→ Common Stock (7,603 underlying) - Exercise of In-Money
Stock Option (right to buy)
2020-11-13−13,282→ 0 totalExercise: $68.50Exp: 2027-03-03→ Common Stock (13,282 underlying) - Sale
Ordinary Common Stock, $0.01 par value
2020-11-16$86.57/sh−7,603$658,192→ 5,617 total - Sale
Ordinary Common Stock, $0.01 par value
2020-11-13$83.82/sh−13,282$1,113,318→ 5,617 total - Exercise of In-Money
Ordinary Common Stock, $0.01 par value
2020-11-16$66.57/sh+7,603$506,132→ 13,220 total
Footnotes (5)
- [F1]This transaction was effectuated pursuant to a Rule 10b-5-1 Plan.
- [F2]The number of securities reported represents an aggregate number of shares sold in multiple open market transactions at an average price of $83.8216. The price reported represents the weighted average price. The Reporting Person undertakes to provide staff of the SEC, the issuer, or a stockholder of the issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
- [F3]All of the stock options in this tranche have vested in full.
- [F4]Not applicable.
- [F5]The remainder of 27,205 options shall vest in equal increments on March 3, 2021 and 2022.